Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: bumblin bob who wrote (189035)	3/11/2009 7:04:16 AM
From: Connor26	Read Replies (1) \| Respond to of 208838

Stock futures pointed to solid gains on Wall Street Wednesday. Dow futures rose 93, or 1.4 percent, to 6,980 and S&P 500 futures advanced 11.4, or 1.6 percent, to 727.40.

To: bumblin bob who wrote (189035)	3/11/2009 9:03:31 AM
From: ACAN	Read Replies (3) \| Respond to of 208838

[CYTX} Cytori Therapeutics Inc Cytori Receives Cell Banking Patent for the Celution® System Cytori Receives Cell Banking Patent for the Celution® System Business Wire SAN DIEGO -- March 11, 2009 Cytori Therapeutics, Inc. (NASDAQ:CYTX) received U.S. Patent No. 7,501,115 (the ‘115 patent), which covers methods of cooling and cryopreserving stem and regenerative cells processed by the Celution® System. This patent provides additional protection for the Company’s cell banking platform, the StemSource® Cell Bank, which Cytori is currently commercializing in both Europe and Asia. The ‘115 patent protects another specific commercial application of the core Celution® System technology, which is covered under U.S. Patent No. 7,390,484 (the ‘484 patent), issued in July 2008. In addition to the ‘484 patent, the Company now has three patents covering various formulations and applications of the Celution® System output. Collectively, these new patents continue to strengthen Cytori’s proprietary position as it relates to automated systems for processing a heterogeneous mixture of stem and regenerative cells within adipose tissue. Cytori currently manufactures the Celution® System in the United States to be sold as part of its StemSource^® Cell Bank platform to hospitals, tissue banks and stem cell storage organizations in Europe and Asia Pacific. The Celution ®900/MB is an automated system that makes simple and affordable an otherwise cumbersome and costly process of preparing cells for storage. The StemSource® Cell Bank enables organizations to offer their patients’ the opportunity to preserve their own adipose-derived stem and regenerative cells for potential future use as needed. Cytori’s intellectual property portfolio includes ten issued U.S. and international patents and numerous applications pending worldwide related to the devices, methods and uses of adipose-derived stem and regenerative cells. The Company believes these patents and applications along with its proprietary know-how, exclusive supply agreements, partnerships, and instrumentation create significant market protection for Cytori.